Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Boehringer Ingelheim's ADC Expansion: A Billion-Dollar Bet on Cancer Therapeutics

Boehringer Ingelheim, the German pharmaceutical giant, has made a significant move in the antibody-drug conjugate (ADC) space, announcing a deal worth up to $991 million with South Korea's AimedBio. This partnership, focused on developing an ADC therapy for cancer, marks the latest in a series of strategic investments by Boehringer Ingelheim in 2025, underlining the company's commitment to expanding its oncology portfolio.

NoahAI News10/15/2025

Bristol Myers Squibb Expands ALS Partnership with Insitro, Committing Over $2 Billion

Bristol Myers Squibb (BMS) has significantly expanded its collaboration with artificial intelligence specialist Insitro, focusing on amyotrophic lateral sclerosis (ALS) drug development. The extended partnership, announced nearly five years after their initial agreement, underscores BMS's commitment to leveraging AI-driven approaches in neurodegenerative disease research.

NoahAI News10/15/2025

BioCryst Acquires Astria Therapeutics for $700M, Bolstering Hereditary Angioedema Portfolio

BioCryst Pharmaceuticals has announced a $700 million acquisition of Astria Therapeutics, significantly expanding its presence in the hereditary angioedema (HAE) market. The deal, expected to close in the first quarter of 2026, will add a promising late-stage injectable drug to BioCryst's existing HAE treatment lineup.

NoahAI News10/15/2025

FDA Awards Second Platform Designation to Krystal Biotech, Validating HSV-1 Vector Technology

The U.S. Food and Drug Administration (FDA) has granted its second platform technology designation to Krystal Biotech for the company's non-replicating HSV-1 viral vector, used in delivering gene therapies. This development comes after the FDA revoked Sarepta Therapeutics' platform designation in July, following a series of deaths linked to their adeno-associated virus vector platform.

NoahAI News10/15/2025

CVS Expands Footprint with Strategic Acquisition of Rite Aid Assets

CVS Health has completed a significant deal to acquire 63 Rite Aid and Bartell Drugs stores across Idaho, Oregon, and Washington, marking a major expansion of its retail pharmacy presence in the Pacific Northwest. The transaction, which comes in the wake of Rite Aid's bankruptcy filing earlier this year, also includes the acquisition of customer prescription files from 626 locations spanning 15 states.

NoahAI News10/15/2025

Stereotaxis and CardioFocus Join Forces to Develop Robotic Pulsed Field Ablation System

Stereotaxis, a leader in robotic technologies for cardiac procedures, has announced a strategic partnership with CardioFocus to develop an innovative robotic pulsed field ablation (PFA) system for the treatment of cardiac arrhythmias. This collaboration marks a significant step forward in combining advanced ablation techniques with robotic precision in cardiac care.

NoahAI News10/15/2025

Biopharma Job Market: Lengthy Searches and Keys to Success

In today's competitive pharmaceutical industry landscape, job seekers are facing extended periods of unemployment, with many professionals experiencing search times of four months or longer. A recent BioSpace LinkedIn poll reveals that 65% of respondents in the past year took at least four months to secure employment, with 35% waiting seven months or more. This trend aligns with broader U.S. labor market data, as the Bureau of Labor Statistics reports that long-term unemployment remains a significant concern.

NoahAI News10/15/2025

NewAmsterdam Pharma Partners with AI Firm Caristo Diagnostics for Innovative Cholesterol Drug Trial

NewAmsterdam Pharma has announced a partnership with UK-based artificial intelligence company Caristo Diagnostics for its upcoming phase 3 Rembrandt Cardiovascular Imaging trial. The study will evaluate the efficacy of NewAmsterdam's cholesterol-lowering drug candidate, a fixed-dose combination of obicetrapib and ezetimibe, in reducing the risk of adverse cardiovascular events.

NoahAI News10/15/2025

Novo Nordisk Acquires Omeros' Zaltenibart in $2.1B Deal, Aims to Advance PNH Treatment

Novo Nordisk has entered into a $2.1 billion agreement with Omeros Corporation to acquire zaltenibart, a MASP-3 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and other rare blood and kidney disorders. The deal, announced on October 15, 2025, marks a significant development in the pharmaceutical industry's approach to rare disease treatments.

NoahAI News10/15/2025

Codis Emerges as New CDMO Powerhouse with Global Spray Drying Capabilities

In a significant development for the pharmaceutical manufacturing landscape, Codis has made its debut as a new contract development and manufacturing organization (CDMO) with an impressive global footprint. The company, formed through the merger of U.S.-based Particle Dynamics and a former EuroAPI facility in the UK, positions itself as a leader in spray drying technology and finished dose manufacturing.

NoahAI News10/15/2025

Tubulis Secures $361M Series C Funding to Advance Next-Generation ADC Platform

German biotech company Tubulis has raised €308 million ($361 million) in a Series C funding round, marking one of the largest financings for a biotech startup this year. The investment will support the advancement of Tubulis' antibody-drug conjugate (ADC) platform and expand clinical development of its lead asset, TUB-040.

NoahAI News10/15/2025

Cartography Biosciences Pushes the Boundaries of Gene Sequencing for Drug Discovery

In a significant development for the pharmaceutical industry, Cartography Biosciences has emerged as a pioneer in leveraging advanced gene sequencing techniques to uncover novel drug targets. The startup, founded during the COVID-19 lockdowns, recently secured a $67 million Series B funding round to further its innovative approach to drug discovery.

NoahAI News10/15/2025

«1...40 41 42...67 »